Endurance Wealth Management’s iShares Core S&P US Growth ETF IUSG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
$440K Hold
4,500
0.06% 134
2023
Q1
$400K Buy
4,500
+100
+2% +$8.52K 0.06% 140
2022
Q4
$359K Buy
4,400
+15
+0.3% +$1.25K 0.05% 138
2022
Q3
$351K Buy
4,385
+30
+0.7% +$2.7K 0.06% 141
2022
Q2
$365K Hold
4,355
0.06% 143
2022
Q1
$460K Sell
4,355
-195
-4% -$20.3K 0.06% 141
2021
Q4
$526K Hold
4,550
0.06% 143
2021
Q3
$466K Buy
4,550
+450
+11% +$47.5K 0.05% 151
2021
Q2
$413K Buy
4,100
+60
+1% +$5.78K 0.05% 162
2021
Q1
$367K Buy
4,040
+40
+1% +$3.6K 0.04% 170
2020
Q4
$355K Hold
4,000
0.04% 161
2020
Q3
$320K Hold
4,000
0.05% 160
2020
Q2
$288K Buy
4,000
+2,000
+100% +$133K 0.05% 156
2020
Q1
$115K Buy
+2,000
New +$132K 0.02% 215

Other funds holding IUSG

Endurance Wealth Management's IUSG Position: Q2 2023 in Review

Endurance Wealth Management held its iShares Core S&P US Growth ETF (IUSG) position steady in Q2 2023 at 4,500 shares worth $440K. The position accounts for 0.06% of the portfolio, ranked #134.

Endurance Wealth Management first reported a position in IUSG in Q1 2020 and has held it in 14 quarters since. The position peaked at $526K in Q4 2021. 566 funds tracked by Wall St. Rank hold IUSG as of Q2 2023.

  • Endurance Wealth Management held 4,500 shares of iShares Core S&P US Growth ETF worth $440K as of Q2 2023.
  • Endurance Wealth Management left its iShares Core S&P US Growth ETF share count unchanged in Q2 2023.
  • iShares Core S&P US Growth ETF made up 0.06% of Endurance Wealth Management's portfolio in Q2 2023, its #134 holding.
  • Endurance Wealth Management first reported a position in iShares Core S&P US Growth ETF in Q1 2020 and has held it in 14 quarters since.
  • Endurance Wealth Management's iShares Core S&P US Growth ETF position peaked at $526K in Q4 2021.
  • 566 funds tracked by Wall St. Rank held iShares Core S&P US Growth ETF as of Q2 2023.

Based on Endurance Wealth Management's 13F filing for Q2 2023, filed 9 Aug 2023.